OPKO Health Inc (OQ:OPK)

Business Focus: Medical & Diagnostic Laboratories

Mar 28, 2024 08:00 am ET
Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business
Transaction to enhance Labcorp's laboratory services network and expand access to the company's high-quality clinical laboratory services
Mar 20, 2024 08:00 am ET
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today positive pharmacokinetic results from its collaborative research combining a proprietary long acting GLP-2 agonist...
Mar 05, 2024 08:52 am ET
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly neutralizing antibody against the human immunodeficiency virus (HIV), at the 2024 Conference...
Feb 27, 2024 04:05 pm ET
OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023. Business highlights from the fourth quarter and subsequent weeks included the following: ModeX advanced its...
Feb 23, 2024 08:31 am ET
Thinking about buying stock in Intuitive Machines, OPKO Health, Ardelyx, AXT Inc, or Clearmind Medicine?
NEW YORK, Feb. 23, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LUNR, OPK, ARDX, AXTI, and CMND.
Feb 22, 2024 04:05 pm ET
OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Tuesday, February 27, 2024. OPKO’s senior management will provide a...
Feb 05, 2024 07:00 am ET
NextPlat Receives Initial Approvals to Launch OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China
E-Commerce Storefront to Initially Support Sales of up to 40 Personal Health and Wellness Products; Final International Certifications and Approvals Required for Formal Launch Expected This Quarter
Jan 09, 2024 04:05 pm ET
OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser’s Option to Purchase Additional Notes
OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced the closing of its previously announced private offering of $230.0 million aggregate principal amount of its Convertible Senior Notes due 2029 (the “Notes”), which amount includes the...
Jan 08, 2024 08:00 am ET
OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference
OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 42nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 at Westin St. Francis hotel in San Francisco. Management will be hosting...
Jan 04, 2024 11:31 pm ET
OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029
OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced the pricing of its private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029 (the “Notes”). The Company granted the initial purchaser in...
Jan 03, 2024 05:05 pm ET
OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029
OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced that it is commencing a private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029 (the “Notes”). The Company also expects to grant the...
Nov 28, 2023 06:00 am ET
BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing
ELMWOOD PARK, N.J., Nov. 28, 2023 /PRNewswire/ -- BioReference® Health, LLC (BRH), a leading specialty laboratory in the United States, announced a strategic collaboration with Prognos Health, a pioneer in providing accessible, quality real world data ("RWD") for the pharmaceutical and life science industries. This collaborative arrangement will offer healthcare providers and researchers unique solutions to inform clinical studies and improve patient outcomes. Combining genetic data and critical biomarkers, means targeted precision therapies based on patients' genetic profiles will be more r
Nov 07, 2023 05:45 am ET
BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™
World-class liquid biopsy testing will be made commercially available to BioReference® customers across the country
Nov 07, 2023 05:45 am ET
BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™
World-class liquid biopsy testing will be made commercially available to BioReference® customers across the country
Nov 06, 2023 04:05 pm ET
OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2023. Business highlights from the third quarter and subsequent weeks included the following: ModeX...
Nov 02, 2023 10:00 am ET
New Clinical Data on OPKO Health’s RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023
OPKO Health, Inc. (NASDAQ: OPK) presented late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology (ASN) Kidney Week in Philadelphia today. These data, presented in a poster titled “Control...
Oct 31, 2023 08:00 am ET
OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2023 after the close of the U.S. financial markets on Monday, November 6, 2023. OPKO’s senior management will provide...
Oct 25, 2023 04:25 pm ET
OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023
OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology (ASN) Kidney Week in Philadelphia on Thursday, November 2, 2023. These data will be...
Oct 12, 2023 10:50 am ET
NextPlat's Florida E-Commerce Development Program to Launch the Online Sales of OPKO Healthcare Products in China on Alibaba's Tmall Global
New E-Commerce Agreement Enables NextPlat to Offer OPKO's Nutraceutical and Veterinary Products for Sale to Chinese Consumers
Sep 29, 2023 09:31 am ET
Thinking about buying stock in Blue Apron Holdings, OceanPal, OPKO Health, Bionomics, or Aytu Biopharma?
NEW YORK, Sept. 29, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APRN, OP, OPK, BNOX, and AYTU.
Sep 28, 2023 04:08 pm ET
ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats
ModeX Therapeutics Inc., an OPKO Health, Inc. company (NASDAQ: OPK), has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S....
Sep 12, 2023 08:30 am ET
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes
Entera Bio Ltd. (NASDAQ: ENTX, “Entera”) and OPKO Biologics, Inc., a subsidiary of OPKO Health, Inc. (NASDAQ: OPK, “OPKO”) have entered into a Research Collaboration Agreement. Under the terms of the Agreement, OPKO will supply its proprietary...
Aug 03, 2023 04:05 pm ET
OPKO Health Reports Second Quarter 2023 Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2023. Second quarter business highlights included the following: U.S. FDA approved NGENLA™ for pediatric growth hormone...
Jul 25, 2023 04:05 pm ET
OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial markets on Thursday, August 3, 2023. OPKO’s senior management will provide a...
Jul 14, 2023 09:31 am ET
Thinking about buying stock in Mind Medicine (MindMed), OPKO Health, Grange Resources, Hyzon Motors, or Bright Minds Biosciences?
NEW YORK, July 14, 2023  InvestorsObserver issues critical PriceWatch Alerts for MNMD, OPK, GRR, HYZN, and DRUG.
Jul 06, 2023 09:31 am ET
Thinking about buying stock in Lucid Group, OPKO Health, Eos Energy Enterprises, Kartoon Studios, or Allarity Therapeutics?
NEW YORK, July 6, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LCID, OPK, EOSE, TOON, and ALLR.
Jun 28, 2023 09:31 am ET
Thinking about buying stock in Marinus Pharmaceuticals, OPKO Health, Xponential Fitness, Plug Power, or Asetek A/S?
NEW YORK, June 28, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRNS, OPK, XPOF, PLUG, and ASTK.
Jun 28, 2023 06:45 am ET
FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone. NGENLA is expected to become available for U.S. prescribing in August 2023.
May 03, 2023 04:05 pm ET
OPKO Health Reports First Quarter 2023 Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2023. First quarter business highlights include the following: OPKO Health’s ModeX Therapeutics, Inc. (ModeX) entered into an...
Apr 25, 2023 04:05 pm ET
OPKO Health to Report First Quarter 2023 Financial Results on May 3, 2023
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2023 after the close of the U.S. financial markets on Wednesday, May 3, 2023. OPKO’s senior management will provide a business...
Mar 09, 2023 08:00 am ET
OPKO Health to Hold Virtual R&D Day on March 20, 2023
OPKO Health, Inc. (NASDAQ: OPK) today announced that it will hold an R&D Day event on March 20, 2023 beginning at 4:00 p.m. Eastern time. The two-hour virtual event will provide an opportunity to hear from OPKO executives about the ModeX...
Mar 08, 2023 08:00 am ET
OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate
OPKO Health, Inc. (NASDAQ: OPK) today announced that ModeX Therapeutics, Inc., an OPKO Health company, entered into an exclusive worldwide license and collaboration agreement with Merck, known as MSD outside the United States and Canada, for the...
Feb 23, 2023 04:05 pm ET
OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended December 31, 2022. Business highlights include the following: Sales are underway by Pfizer for NGENLA® (somatrogon) in 15 countries...
Feb 16, 2023 11:41 am ET
OPKO Health to Report Fourth Quarter 2022 Financial Results on February 23, 2023
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2022 after the close of the U.S. financial markets on Thursday, February 23, 2023. OPKO’s senior management will provide a...
Feb 09, 2023 06:05 am ET
BioReference Now Offers the Only FDA-Approved Dual-Stain Triage Test to Enhance Cervical Cancer Screenings
CINtec® PLUS Cytology offered as a reflex test when cytology is NILM and HPV positive
Jan 03, 2023 08:00 am ET
OPKO Health to Present at the 41st Annual J.P. Morgan Healthcare Conference
OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 41st Annual J.P. Morgan Healthcare Conference being held January 9-12, 2023 at the Westin St. Francis in San Francisco. Management will be hosting...
Nov 08, 2022 04:05 pm ET
OPKO Health Reports Third Quarter 2022 Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended September 30, 2022. Business highlights for the third quarter of 2022 and subsequent weeks include the following: Pfizer’s NGENLA®...
Nov 01, 2022 08:00 am ET
OPKO Health to Report Third Quarter 2022 Financial Results on November 8, 2022
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2022 after the close of the U.S. financial markets on Tuesday, November 8, 2022. OPKO’s senior management will provide...
Sep 15, 2022 04:05 pm ET
Jon Cohen and Michael Hansen Join Talkspace’s Board of Directors
Shareholders of Talkspace, Inc. (Nasdaq: TALK) today elected Jon Cohen, M.D., to the virtual behavioral healthcare company’s board of directors and approved all other shareholder proposals during the company’s first Annual Meeting of Stockholders....
Aug 16, 2022 04:29 pm ET
OPKO Health Announces Leadership Changes for BioReference Laboratories
OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced that Jon R. Cohen, M.D., is retiring from his role as Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior...
Aug 04, 2022 04:05 pm ET
OPKO Health Reports 2022 Second Quarter Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2022. Business highlights for the second quarter of 2022 and subsequent weeks include the following: Acquired...
Jul 25, 2022 04:05 pm ET
OPKO Health to Report Second Quarter 2022 Financial Results on August 4, 2022
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2022 after the close of the U.S. financial markets on Thursday, August 4, 2022. OPKO’s senior management will provide a...
Jun 02, 2022 08:00 am ET
OPKO Health to Present at the 2022 Jefferies Healthcare Conference
OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the 2022 Jefferies Healthcare Conference taking place June 8-10, 2022 in New York City. Management will be participating in a fireside chat on Thursday, June...
May 09, 2022 04:05 pm ET
OPKO Health Reports 2022 First Quarter Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2022. Business Highlights Business highlights for the first quarter of 2022 and subsequent weeks include the following:...
May 09, 2022 09:23 am ET
OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases
OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical and diagnostics company, today announced the acquisition of ModeX Therapeutics, Inc. a privately held biotechnology company focused on developing innovative multi-specific immune...
May 05, 2022 04:05 pm ET
OPKO Health to Report First Quarter 2022 Financial Results on May 9, 2022
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2022 after the close of the U.S. financial markets on Monday, May 9, 2022. OPKO’s senior management will provide a business update...
Mar 16, 2022 07:30 am ET
GeneDx Announces Discovery of 200 New and Expanded Genetic Conditions
New research underscores the value of sharing genomic information to advance gene matching for diagnosis and discovery
Mar 01, 2022 05:00 am ET
Saol Therapeutics and GeneDx, Inc. Collaborate to Detect Patients with Rare Mitochondrial Disease
ROSWELL, Ga., March 1, 2022 /PRNewswire/ -- Saol Therapeutics, a company researching new treatments for rare diseases, is pleased to announce a collaboration with GeneDx, Inc. a leader in genomic analysis, a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), to assist in identifying patients diagnosed with a rare mitochondrial disease, Pyruvate Dehydrogenase Complex Deficiency (PDCD) who may be eligible to participate in a Phase 3 clinical trial.  PDCD affects less than 300 children in the United States annually and lacks any FDA-approved treatme
Feb 24, 2022 04:05 pm ET
OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended December 31, 2021. Business Highlights Business highlights for the fourth quarter of 2021 and subsequent weeks include the following:...
Feb 17, 2022 08:00 am ET
OPKO Health to Report Fourth Quarter 2021 Financial Results on February 24, 2022
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2021 after the close of the U.S. financial markets on Thursday, February 24, 2022. OPKO’s senior management will provide a...
Feb 15, 2022 11:08 am ET
Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency
Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA™ (somatrogon), a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone. NGENLA provides pediatric patients, their caregivers and healthcare providers with a new treatment option for growth hormone deficiency (GHD) that reduces the frequency of required injections from once daily to once w
Feb 03, 2022 08:30 am ET
RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP
OPKO Health, Inc. (NASDAQ: OPK) announces that Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has initiated the commercial launch of RAYALDEE® (extended release calcifediol) in Germany, the first launch of RAYALDEE outside the U.S. VFMCRP is...
Jan 21, 2022 04:30 pm ET
Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency
Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for somatrogon. Somatrogon is an investigational once-weekly long-acting recombinant human growth hormone for the treatment of growth hormone deficiency (GHD) in pediatric patients. Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward.
Jan 20, 2022 08:00 am ET
Japan’s MHLW Approves Pfizer and OPKO’s NGENLA® (Somatrogon), a New Long-Acting Treatment for Pediatric Growth Hormone Deficiency
Pfizer Japan Inc. and OPKO Health, Inc. (NASDAQ: OPK) announced today that the next generation long-acting growth hormone injection, NGENLA® (somatrogon) Inj. 24 mg Pens and 60 mg Pens, has been approved by the Ministry of Health, Labour and...
Jan 18, 2022 08:31 am ET
Thinking about buying stock in Polarityte, Opko Health, Ion Geophysical, National CineMedia, or Playtika?
NEW YORK, Jan. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTE, OPK, IO, NCMI, and PLTK.
Jan 18, 2022 07:00 am ET
Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform
Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, and OPKO Health, Inc. (Nasdaq: OPK) (“OPKO”), a multinational biopharmaceutical and diagnostics company, today announced they have signed a definitive...
Jan 05, 2022 04:05 pm ET
OPKO Health to Participate in the 40th Annual J.P. Morgan Healthcare Conference
OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the 40th Annual J.P. Morgan Healthcare Conference being held virtually January 10-13, 2022. Management will be hosting one-on-one meetings with investors and will be participating in a virtual fireside chat on Wednesday, January 12th at 3:00 p.m. Eastern time.
Dec 23, 2021 09:45 am ET
Thinking about buying stock in Allakos, 22nd Century Group, Osmotica Pharmaceuticals, Banco Santander SA, or Opko Health?
NEW YORK, Dec. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALLK, XXII, OSMT, SAN, and OPK.
Dec 23, 2021 08:00 am ET
OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients
OPKO Health, Inc. (NASDAQ: OPK) announces preliminary topline results from its Phase 2 trial with RAYALDEE® to treat mild-to-moderate COVID-19. This study builds on increasing medical evidence that vitamin D repletion therapy can mitigate the...
Dec 08, 2021 08:00 am ET
OPKO Health Receives U.S. FDA Approval for the 4Kscore® Test
OPKO Health, Inc. (NASDAQ: OPK) today announced that the U.S. Food and Drug Administration (FDA) has approved OPKO’s 4Kscore Test. This test is approved for use in men age 45 and older who have not had a prior prostate biopsy or are biopsy negative...
Dec 06, 2021 08:00 am ET
OPKO Health Announces the Passing of Director Dr. Richard Lerner
OPKO Health, Inc. (NASDAQ: OPK) announces that Director Richard A. Lerner, M.D. passed away on December 2nd at the age of 83.   Dr. Lerner had served as a Director of OPKO Health since 2007. The Board of Directors and staff of OPKO extend their...
Nov 29, 2021 09:25 am ET
BioReference Laboratories Announces Readiness for COVID-19 Testing if the Omicron COVID-19 Variant Emerges in The U.S.
ELMWOOD PARK, N.J., Nov. 29, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), announced COVID-19 testing preparedness for the Omicron Variant. BioReference's PCR diagnostic tests for SARS-CoV-2 COVID-19 are based on recognizing specific RNA target genes that are common to all coronaviruses.
Nov 29, 2021 08:00 am ET
OPKO Health Announces Participation in Piper Sandler 33rd Annual Virtual Healthcare Conference
OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference taking place November 30 through December 2, 2021. A pre-recorded company fireside chat is...
Oct 28, 2021 04:15 pm ET
OPKO Health Reports 2021 Third Quarter Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended September 30, 2021. Business Highlights Health Canada approved NGENLA™ (somatrogon) injection for pediatric growth hormone...
Oct 25, 2021 10:57 am ET
OPKO Health to Report Third Quarter 2021 Financial Results on October 28, 2021
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended September 30, 2021, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, October 28, 2021....
Oct 12, 2021 08:00 am ET
Krystal Biotech and GeneDx Announce Collaboration to Provide No-charge Genetic Testing for Patients with Suspected Dystrophic Epidermolysis Bullosa (DEB)
Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, and GeneDx, Inc., a leader in genomic analysis and a wholly-owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company...
Sep 24, 2021 04:24 pm ET
Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for somatrogon, a once-weekly long-acting...
Sep 21, 2021 02:30 pm ET
GeneDx Announces the Sequencing of More Than 300,000 Clinical Patient Exomes
GAITHERSBURG, Md., Sept. 21, 2021 /PRNewswire/ -- GeneDx, Inc., a leader in genomic analysis, a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced it has completed clinical genetic exome sequencing for more than 300,000 patients, making the company's dataset the largest of its kind in the world. Supported by matching phenotypes, the company's market-leading genomic analysis and interpretation capabilities have created a diagnosis and discovery engine advancing genetic medicine worldwide.
Sep 14, 2021 08:00 am ET
LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in China and Other Asian Territories
LeaderMed Health Group Limited, a pharmaceutical development company with operations based in Asia, and OPKO Health, Inc. (NASDAQ: OPK), a diversified healthcare company focused on diagnostics and pharmaceuticals, announce the formation of a joint...
Aug 30, 2021 04:17 pm ET
OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 Outpatients
OPKO Health, Inc. (NASDAQ: OPK) announces the completion of enrollment in its Phase 2 trial with RAYALDEE® as a treatment for mild-to-moderate COVID-19. The U.S. trial, “A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and...
Aug 30, 2021 09:04 am ET
OPKO Health to Participate in Two Upcoming Investment Conferences
OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in two upcoming virtual investor conferences. 14th Annual Barrington Research Fall Conference, September 9, 2021. Management will be available for one-on-one and...
Aug 26, 2021 09:18 am ET
Rite Aid, in Partnership with the U.S. Department of Health and Human Services, BioReference Laboratories and New York State, Announces ‘Back to School’ COVID-19 Testing Program
Rite Aid (NYSE: RAD) and the U.S. Department of Health and Human Services (HHS), together with BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), announced a ‘Back to School’ COVID-19 testing program offering students at New York State public schools the opportunity for free COVID-19 testing prior to or at the
Aug 16, 2021 09:55 am ET
BioReference Laboratories Acquires U.S. Ariosa Centralized Laboratory Prenatal Testing Business
ELMWOOD PARK, N.J., Aug. 16, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the acquisition of the U.S. Ariosa centralized laboratory prenatal testing business from Roche.
Jul 29, 2021 04:05 pm ET
OPKO Health Reports 2021 Second Quarter Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended June 30, 2021. Business Highlights BioReference Laboratories (BRL) test volume increased 32% compared with the second quarter of 2020....
Jul 20, 2021 08:00 am ET
OPKO Health to Report Second Quarter 2021 Financial Results on July 29, 2021
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended June 30, 2021, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, July 29, 2021. OPKO’s senior...
Jul 12, 2021 08:00 am ET
OPKO Health Licenses Oligonucleotide Therapeutics Platform to CAMP4 Therapeutics
OPKO Health, Inc. (NASDAQ: OPK) today announced it has entered into an exclusive worldwide agreement with privately held CAMP4 Therapeutics Corporation (CAMP4) for the development, manufacture and commercialization of therapeutics utilizing the...
Jul 08, 2021 04:05 pm ET
OPKO Health to Present at the Ladenburg Thalmann Healthcare Conference
OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the Ladenburg Thalmann Healthcare Conference being held virtually July 13-14, 2021. Management will be interviewed in a fireside chat format on Tuesday, July...
Jun 22, 2021 08:00 am ET
OPKO Health Appoints Katherine Stueland as President and CEO of GeneDx
OPKO Health, Inc. (NASDAQ: OPK) today announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., the global genomics subsidiary of OPKO’s BioReference Laboratories. Ms. Stueland joins GeneDx from...
Jun 22, 2021 07:39 am ET
BioReference Laboratories Announces First COVID-19 Testing Program for Cruise Industry
MIAMI, June 22, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced a COVID-19 testing program for U.S. based crew and guests who cruise with Royal Caribbean Group, helping provide a safe environment for travelers.
Jun 21, 2021 08:03 am ET
OPKO Health to Develop and Commercialize RAYALDEE® in Greater China with Nicoya Therapeutics
OPKO Health, Inc. (NASDAQ: OPK) today announced that its subsidiary EirGen Pharma has entered into an agreement with Nicoya Macau Limited, an affiliate of Nicoya Therapeutics (Nicoya), for the development and commercialization in Greater China...
Jun 17, 2021 07:00 am ET
OPKO Health Announces Sale of its Sterile Fill and Finish Manufacturing Facility in Ireland
OPKO Health, Inc. (NASDAQ: OPK) announces that its subsidiary, EirGen Pharma, Ltd., has entered into a definitive agreement to sell one of its facilities in Waterford, Ireland to Horizon Therapeutics plc (Nasdaq: HZNP) for $65 million in cash less...
May 28, 2021 08:00 am ET
Cocrystal Pharma Announces the Passing of Chairman, CEO and Co-founder Dr. Gary Wilcox
With great sadness, Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”) announces that Gary Wilcox, Ph.D., Chairman, CEO and co-founder, suddenly passed away Wednesday, May 26 at the age of 74. The Board of Directors and staff of...
May 27, 2021 08:30 am ET
OPKO Health to Participate in the Jefferies Virtual Healthcare Conference
OPKO Health, Inc. (NASDAQ: OPK) announced today that management will be participating in the Jefferies Virtual Healthcare Conference being held June 1-4, 2021. Management will be interviewed in a fireside chat on Wednesday, June 2 at 11:30 a.m....
May 24, 2021 07:30 am ET
OPKO Health Reports Transfer of Licensed Rights to RAYALDEE® in Japan to Vifor
OPKO Health, Inc. (NASDAQ: OPK) today announced a transfer of the licensed rights to RAYALDEE® in Japan from Japan Tobacco Inc. (JT) to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). On May 17, 2021, JT notified OPKO of its decision to...
May 07, 2021 01:33 pm ET
OPKO Health Enters into Exchange Agreements with Certain 4.5% Convertible Senior Noteholders
OPKO Health, Inc. (NASDAQ: OPK) has entered into exchange agreements with certain noteholders of the Company’s 4.50% Convertible Senior Notes due 2025 (“Notes”). The noteholders have agreed to exchange $55.42 million of the Company’s outstanding...
Apr 28, 2021 04:05 pm ET
OPKO Health Reports 2021 First Quarter Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2021. Business Highlights BioReference Laboratories test volume increased 158% compared with the first quarter of 2020. During...
Apr 22, 2021 08:00 am ET
OPKO Health to Report First Quarter 2021 Financial Results on April 28, 2021
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2021, as well as discuss financial guidance, after the close of the U.S. financial markets on Wednesday, April 28, 2021. OPKO’s...
Feb 18, 2021 04:05 pm ET
OPKO Health Reports 2020 Fourth Quarter Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended December 31, 2020. Business Highlights BioReference Laboratories’ volume in the fourth quarter of 2020 increased 170% compared to...
Feb 03, 2021 09:01 am ET
OPKO Health to Report Fourth Quarter 2020 Financial Results on February 18, 2021
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2020, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, February 18, 2021....
Jan 28, 2021 08:00 am ET
New Drug Application Submitted to PMDA in Japan for Somatrogon, to Treat Pediatric Patients with Growth Hormone Deficiency
OPKO Health, Inc. (NASDAQ: OPK) announced today that its partner, Pfizer Japan Inc., submitted a New Drug Application (NDA) to the Ministry of Health, Labour, and Welfare in Japan for somatrogon, a long-acting recombinant human growth hormone that...
Jan 26, 2021 07:30 am ET
OPKO Health's GeneDx Adds Repeat Expansion Analysis Genetic Tests for Diagnosis of Spinocerebellar Ataxia (SCA), Friedreich Ataxia, and Other Common Forms of Hereditary Ataxia
GAITHERSBURG, Md., Jan. 26, 2021 /PRNewswire/ -- GeneDx, Inc., a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today launched several new genetic tests, including repeat expansion analysis for spinocerebellar ataxia (SCA), Friedreich ataxia, and other common forms of hereditary ataxias. With these additions, GeneDx has created a comprehensive and affordable offering that covers the vast majority of genes involved with pediatric-onset and adult-onset ataxias.
Jan 26, 2021 07:00 am ET
OPKO Health's BioReference Laboratories Team-up with the National Basketball Association and National Hockey League to Provide Players and Staff with COVID-19 Testing
ELMWOOD PARK, N.J., Jan. 26, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced COVID-19 testing agreements for players and officials, as well as team and league staff for the 2020-2021 seasons for the National Basketball Association (NBA) and National Hockey League (NHL).
Jan 13, 2021 02:40 pm ET
OPKO Health's BioReference Laboratories Introduces Scarlet Health™, an In-Home Diagnostic Service to Expand Digital Health Access
ELMWOOD PARK, N.J., Jan. 13, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today introduced Scarlet Health™, an in-home, fully integrated digital platform providing access to on-demand diagnostic services. Scarlet has been designed similarly to tools consumers use daily, in order to provide ease-of-use and ubiquitous conveniences. 
Jan 13, 2021 06:00 am ET
Sian Capital Urges OPKO Health to Address Apparently Misleading 4Q’20 Guidance
Sian Capital, LLC (together with its affiliates, “Sian” or “we”), a sizable stockholder of OPKO Health, Inc. (NASDAQ: OPK) (“OPKO” or the “Company”), today announced that it sent a letter to the Company’s Board of Directors (the “Board”) on...
Jan 05, 2021 08:00 am ET
OPKO Health to Present at the 39th Annual J.P. Morgan Healthcare Conference
OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the 39th Annual J.P. Morgan Healthcare Conference being held virtually on January 11-14, 2021. Management will be hosting one-on-one meetings with investors...
Jan 04, 2021 11:05 am ET
OPKO Health's BioReference Laboratories Reports Results of the Largest COVID-19 Public School Testing Program Nationwide
ELMWOOD PARK, N.J., Jan. 4, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced the results of COVID-19 molecular PCR tests for public schools throughout New York City's boroughs, with a positivity rate of 0.47 percent.
Jan 04, 2021 06:45 am ET
US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the US Food and Drug Administration (FDA) has accepted for filing the initial Biologics License Application (BLA) for somatrogon, a long-acting human growth hormone that is intended to be administered once-weekly for the treatment of pediatric patients with growth hormone deficiency (GHD).
Dec 31, 2020 07:30 am ET
Buffalo Bills and OPKO Health's BioReference Laboratories Initiate the First Large Scale, Mandatory COVID-19 Fan Testing Program
ORCHARD PARK, N.Y., Dec. 31, 2020 /PRNewswire/ -- Buffalo Bills, 2020 AFC East Division Champions, and BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced they will be performing fan testing for the AFC Divisional Wild Card playoff game at Bills Stadium in Orchard Park.
Dec 21, 2020 08:00 am ET
OPKO Health Appoints Dr. Roger Medel to its Board of Directors
OPKO Health, Inc. (NASDAQ: OPK) today announced the appointment of Roger Medel, M.D. as an independent member of its Board of Directors, effective December 18, 2020. With this appointment, the OPKO Health Board has 11 Directors, including seven...
Nov 20, 2020 04:45 pm ET
Sian Capital Sends Letter to OPKO Health Regarding its Decision to Apparently Withhold Rayaldee From Many Patients Amidst COVID-19’s Second Wave
Sian Capital, LLC (together with its affiliates, “Sian” or “we”), a sizable stockholder with beneficial ownership of approximately 3% of OPKO Health, Inc.'s (NASDAQ: OPK) (“OPKO” or the “Company”) outstanding common stock, today sent a letter to...
Nov 12, 2020 06:30 pm ET
Sian Capital Issues Open Letter to Stockholders of OPKO Health
Highlights that Just Two Weeks after Sian Capital Sent Its 220 Demand Letter to OPKO, the Company has Agreed to Release A Subset of the Documents Requested, Which We Believe Will Validate our Valuation Assertions Announces OPKO Has Agreed to Enact...
Nov 11, 2020 09:10 am ET
OPKO Health to Participate in Three Upcoming Investment Conferences
OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in three upcoming virtual investor conferences. H.C. Wainwright 6th Annual Israel Virtual Conference, November 12, 2020. Management will participate in a...
Oct 29, 2020 04:05 pm ET
OPKO Health Reports 2020 Third Quarter Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended September 30, 2020. Third Quarter Business Highlights BioReference Laboratories’ COVID-19 PCR testing volume increased 61% over the...
Oct 20, 2020 08:00 am ET
OPKO Health's BioReference Laboratories Launches Multiplex COVID-19 and Influenza A/B Test
ELMWOOD PARK, N.J., Oct. 20, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), is now accepting specimens for a new multiplex COVID-19 and influenza test for use by healthcare providers, clinics and health systems throughout the United States, to aid in the diagnosis of COVID-19 and Influenza A or B (flu).
Oct 13, 2020 12:50 pm ET
OPKO Health to Report Third Quarter 2020 Financial Results on October 29, 2020
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended September 30, 2020, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, October 29, 2020....
Sep 15, 2020 07:00 am ET
OPKO Health Initiates Clinical Trial of RAYALDEE in COVID-19 Patients
OPKO Health, Inc. (NASDAQ: OPK) announces the initiation of a Phase 2 trial with RAYALDEE® as a treatment for mild-to-moderate COVID-19.  The trial, “A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of...
Sep 02, 2020 04:05 pm ET
OPKO Health to Participate in Two September Investment Conferences
OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in two upcoming virtual investor conferences. 13th Annual Barrington Research Fall Conference, September 9, 2020. Management will be available for one-on-one...
Aug 06, 2020 08:00 am ET
OPKO Health's GeneDx Adds GenomeXpress to Its Industry-Leading Clinical Genomics Portfolio
GAITHERSBURG, Md., Aug. 6, 2020 /PRNewswire/ -- GeneDx, Inc., a subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the launch of GenomeXpress, a rapid genome sequencing test. Verbal GenomeXpress results of pathogenic and/or likely pathogenic variants in known disease causing genes are delivered to the ordering healthcare provider within approximately seven days after the start of testing. A written report for all confirmed variants is sent to the provider within approximately 14 days after start of testing. With the addition of GenomeXpress, G
Aug 05, 2020 03:35 pm ET
OPKO Health to Participate in BTIG Virtual Biotechnology Conference
OPKO Health, Inc. (NASDAQ: OPK) today announced that management will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 10, 2020 at 9:00 a.m. Eastern time.  In addition, management will be hosting...
Jul 30, 2020 04:05 pm ET
OPKO Health Reports 2020 Second Quarter Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended June 30, 2020. Second Quarter Business Highlights BioReference Laboratories increased COVID-19 testing nationwide:  During...
Jul 27, 2020 08:00 am ET
OPKO Health to Report Second Quarter 2020 Financial Results on July 30, 2020
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended June 30, 2020, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, July 30, 2020. OPKO’s senior...
Jul 21, 2020 09:31 am ET
Thinking about buying stock in New Age Beverages, Lexicon Pharmaceuticals, Miragen Therapeutics, Opko Health, or Niu Technologies?
NEW YORK, July 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NBEV, LXRX, MGEN, OPK, and NIU.
Jul 20, 2020 02:45 pm ET
OPKO Health's BioReference Laboratories Awarded Commercial Surge Capacity Testing for COVID-19 Emergency Response Contract by Centers for Disease Control and Prevention (CDC)
ELMWOOD PARK, N.J., July 20, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced it will accept an Indefinite Delivery Indefinite Quantity (IDIQ) contract award to provide Commercial Surge Capacity Testing for COVID-19 Emergency Response to the Centers for Disease Control and Prevention (CDC).
Jul 09, 2020 08:00 am ET
Major League Soccer Chooses OPKO Health's BioReference Laboratories to Provide COVID-19 Testing for Players and Employees
ELMWOOD PARK, N.J., July 9, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), will conduct COVID-19 testing for all Major League Soccer (MLS) players as well as match officials, and Club and League staff participating in the MLS is Back Tournament. MLS has chosen BioReference as its laboratory to assist in informing its return-to-play policies for the Tournament kicking off in Orlando in early July.
Jul 01, 2020 10:30 am ET
Thinking about buying stock in Pfizer Inc, Opko Health, Macy's, Spirit Airlines, or MGM Resorts?
NEW YORK, July 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, OPK, M, SAVE, and MGM.
Jul 01, 2020 08:15 am ET
OPKO Health's BioReference Laboratories Reports Results of COVID-19 Testing for Almost One Quarter of a Million Nursing Home and Live-in Facility Employees
ELMWOOD PARK, N.J., July 1, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced the results of COVID-19 molecular PCR and antibody tests for nursing home and live-in facility employees.
Jun 09, 2020 08:00 am ET
OPKO Health Announces Positive Top-Line Results of Phase 3 Efficacy and Safety Study of Somatrogon for the Treatment of Japanese Children with Growth Hormone Deficiency
Following last October’s announcement of successful results of the global Phase 3 study of once-weekly somatrogon, an investigational agent for the treatment of pediatric growth hormone deficiency (pGHD), OPKO Health Inc. (NASDAQ: OPK) announced...
Jun 01, 2020 08:00 am ET
FDA Authorizes OPKO Health Clinical Trial Evaluating RAYALDEE in COVID-19 Patients
OPKO Health, Inc. (NASDAQ: OPK) today announced that the U.S. Food and Drug Administration (FDA) has authorized OPKO to undertake a Phase 2 trial with RAYALDEE® as a treatment for patients with mild-to-moderate COVID-19.  The trial, entitled “A...
May 27, 2020 08:00 am ET
OPKO Health to Present at the Jefferies Virtual Healthcare Conference
OPKO Health, Inc. (NASDAQ:  OPK) announced today that management will be participating in the Jefferies Virtual Healthcare Conference being held June 2-4, 2020.  Management will be hosting one-on-one meetings with investors via organized conference...
May 18, 2020 08:00 am ET
MagnaCare and BioReference Laboratories Bring COVID-19 Antibody Testing to New York Labor Groups
NEW YORK, May 18, 2020 /PRNewswire/ -- MagnaCare today announced a collaboration with BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), to bring COVID-19 antibody testing to their Labor clients in the New York metropolitan area. Through this collaboration with BioReference, MagnaCare will offer on-site antibody blood testing to Labor members, delivering valuable information as the city, employers and individuals plan return-to-work strategies.
May 13, 2020 04:05 pm ET
OPKO Health's BioReference Laboratories Launches COVID-19 Employer Solution
ELMWOOD PARK, N.J., May 13, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today launched the BioReference Employer Solution, a COVID-19 screening program that assists employers' decisions about return-to-work policies.
May 13, 2020 08:30 am ET
OPKO Health's BioReference Laboratories and Westchester Medical Center Health Network Enter Into Strategic Laboratory Collaboration to Deliver Operational and Diagnostic Services
ELMWOOD PARK, N.J., May 13, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced a strategic collaboration with the Westchester Medical Center Health Network (WMCHealth), a 1,700-bed healthcare system headquartered in Valhalla, New York, to provide full laboratory administrative services, laboratory operations, reference testing and outpatient laboratory services.
May 08, 2020 09:00 am ET
OPKO Health's BioReference Laboratories Launches COVID-19 Antibody Screening for New York City Residents
ELMWOOD PARK, N.J., May 8, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the launch of COVID-19 antibody screening available to New York City residents in partnership with New York City Health and Hospital Corporation (NYC Health + Hospitals). Testing will initially be performed for 140,000 residents at five locations across all five boroughs, with more testing sites to open in the next several weeks. Test results will be available through BioReference's Patient Portal, accessible by smartphone, tablet, desktop or traditional US Ma
May 06, 2020 04:05 pm ET
OPKO Health Reports 2020 First Quarter Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2020. Business Highlights BioReference Laboratories launched COVID-19 testing nationwide:  On March 13, 2020, BioReference...
Apr 30, 2020 04:05 pm ET
OPKO Health to Report First Quarter 2020 Financial Results on May 6, 2020
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2020, as well as discuss financial guidance, after the close of the U.S. financial markets on Wednesday, May 6, 2020. CONFERENCE...
Apr 29, 2020 01:35 pm ET
OPKO Health's BioReference Laboratories in Partnership with New York State Initiates Testing for COVID-19 Antibodies
ELMWOOD PARK, N.J., April 29, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), announced that beginning today it will offer antibody blood tests to detect an immune response after infection with the COVID-19 virus. Antibody testing and molecular diagnostic testing for COVID-19 are available to healthcare providers nationwide. In addition, under an agreement with New York State, BioReference will begin testing thousands of people per day for COVID-19 antibodies, starting today with MTA employees.
Apr 22, 2020 08:00 am ET
Somatrogon Phase 3 Pediatric Trial Results will be presented on June 8 at ENDO Online 2020
OPKO Health, Inc. (NASDAQ:  OPK) today provided an update on two abstracts regarding the global Phase 3 somatrogon pediatric trial evaluating somatrogon dosed once weekly in pre-pubertal children with growth hormone deficiency (GHD).  The data from...
Apr 06, 2020 09:00 am ET
OPKO Health's BioReference Laboratories Partners with Hospitals Nationwide to Provide Prioritized Testing to Inpatients with Suspected Coronavirus Disease 2019 (COVID-19)
ELMWOOD PARK, N.J., April 6, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced that it will continue to prioritize COVID-19 testing for hospital inpatients and critically ill patients around the country.
Mar 25, 2020 08:00 am ET
OPKO Health Reports Interim Results for Two Ongoing RAYALDEE Studies
OPKO Health, Inc. (NASDAQ: OPK) today reported interim results from an ongoing Phase 4 clinical trial comparing RAYALDEE® with three common treatment regimens for secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic...
Mar 24, 2020 09:00 am ET
OPKO Health's BioReference Laboratories and City of Miami Provide Testing for Coronavirus Disease 2019 (COVID-19)
ELMWOOD PARK, N.J., March 24, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced a collaboration with the City of Miami to provide coronavirus disease 2019 (COVID-19) testing. BioReference will provide COVID-19 testing at drive-through locations for Miami residents by appointment.
Mar 23, 2020 07:00 am ET
OPKO Health's BioReference Laboratories and City of Detroit Provide Testing for Coronavirus Disease 2019 (COVID-19)
ELMWOOD PARK, N.J., March 23, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced a collaboration with the City of Detroit to provide coronavirus disease 2019 (COVID-19) testing. BioReference will provide COVID-19 testing at drive-through locations for Detroit residents by appointment.
Mar 20, 2020 11:54 am ET
OPKO Health's BioReference Laboratories and State of New Jersey Provide Testing for Coronavirus Disease 2019 (COVID-19)
ELMWOOD PARK, N.J., March 20, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced a collaboration with the State of New Jersey to provide coronavirus disease 2019 (COVID-19) testing across the State. BioReference will provide testing for the first NJ drive-through facilities in Burlington, Essex, Hudson, Ocean and Union Counties.
Mar 17, 2020 02:26 pm ET
OPKO Health's BioReference Laboratories and NYC Health + Hospitals Enter into Laboratory Collaboration to Provide Testing for Coronavirus Disease 2019 (COVID-19)
ELMWOOD PARK, N.J., March 17, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced a collaboration with the New York City Health and Hospital Corporation (NYC Health + Hospitals) to provide coronavirus disease 2019 (COVID-19) testing. NYC Health + Hospitals is the largest public health care system in the nation serving more than a million New Yorkers annually in more than 70 patient care locations across the city's five boroughs.
Mar 10, 2020 04:32 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of OPKO Health, Inc. – OPK
Pomerantz LLP is investigating claims on behalf of investors of OPKO Health, Inc. (“OPKO” or the “Company”) (NASDAQ: OPK). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Feb 26, 2020 04:05 pm ET
OPKO Health Reports 2019 Fourth Quarter Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended December 31, 2019. Business Highlights Successful Phase 3 results for Somatrogon, an investigational long-acting human growth hormone...
Feb 20, 2020 12:15 pm ET
OPKO Health to Report Fourth Quarter 2019 Financial Results on February 26, 2020
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2019, as well as provide guidance on expected revenues and operating expenses for the first quarter and full year 2020, after...
Dec 19, 2019 12:00 pm ET
BioReference Laboratories Showcases 2019 Growth through the Addition of Cutting Edge Tests, Greater Access to Services, and Optimized Patient Experience
BioReference Laboratories, Inc., an OPKO Health Company, along with its genetics and genomics laboratory, GeneDx, Inc., and oncology, urology and women’s health division, GenPath Diagnostics, are pleased to provide a 2019 business update,...
Dec 19, 2019 08:00 am ET
OPKO Health to Present at the 38th Annual J.P. Morgan Healthcare Conference
OPKO Health, Inc. (OPK) announced today that management will be participating in the 38th Annual J.P. Morgan Healthcare Conference being held January 13-16, 2020 at the Westin St. Francis in San Francisco.  Management will be hosting one-on-one...
Nov 26, 2019 08:00 am ET
OPKO Health to Participate in the 31st Annual Piper Jaffray Healthcare Conference
OPKO Health, Inc. (OPK) today announced that Company management will be participating in the 31st Annual Piper Jaffray Healthcare Conference being held December 3-5, 2019 at the Lotte New York Palace in New York City.  Management will be hosting...
Nov 15, 2019 08:00 am ET
Novitas Issues Final Local Coverage Determination for the 4Kscore® Test
OPKO Health, Inc. (OPK) today announced that Novitas Solutions, Inc. has issued its final Local Coverage Determination (LCD) for Medicare payments for the 4Kscore® test with defined coverage criteria, effective December 30, 2019.  Full text of the...
Nov 05, 2019 04:05 pm ET
OPKO Health Reports 2019 Third Quarter Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended September 30, 2019. Business Highlights Somatrogon meets primary and key secondary endpoints in global Phase 3 trial:  On October 21,...
Nov 04, 2019 08:00 am ET
BioReference Laboratories and GeneDx to Present at NSGC 2019, Demonstrating Commitment to Genetic Counselors and the Research of Rare Genetic Disorders
BioReference Laboratories, Inc., an OPKO Health Company, along with its genetics and genomics laboratory, GeneDx, and women’s health division, GenPath, today announced the presentation of new research from its genetics program at the National...
Nov 01, 2019 08:00 am ET
OPKO Health to Report Third Quarter 2019 Financial Results on November 5, 2019
OPKO Health, Inc. (NASDAQ: OPK) plans to report its operating and financial results for the three months ended September 30, 2019, as well as provide guidance on expected revenues and operating expenses for the third quarter 2019, after the close...
Oct 24, 2019 06:57 pm ET
OPKO Health, Inc. Announces Pricing of its Offering of Common Stock
OPKO Health, Inc. (“OPKO Health” or the “Company”) (NASDAQ:OPK) today announced the pricing of an underwritten public offering of 50 million shares of its common stock (the “Shares”) at a price of $1.50 per Share, resulting in gross proceeds to the...
Oct 22, 2019 04:05 pm ET
OPKO Health, Inc. Announces Proposed Offering of Common Stock
OPKO Health, Inc. (“OPKO Health” or the “Company”) (NASDAQ:OPK) today announced that, subject to market and other conditions, it intends to offer and sell up to $100 million of shares of its common stock (the “Shares”) in an underwritten public...
Oct 21, 2019 08:00 am ET
OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
OPKO Health Inc. (NASDAQ: OPK) and Pfizer Inc. (NYSE: PFE) announced today that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with growth hormone deficiency (GHD) met its primary endpoint of...
Aug 29, 2019 09:24 am ET
OPKO Completes Pivotal Phase 3 Study for Somatrogon (hGH-CTP), an Investigational Long-Acting Growth Hormone Being Studied for the Treatment of Children With Growth Hormone Deficiency
OPKO Health, Inc. (NASDAQ: OPK) today announced that the last patient has completed the final visit in the Company’s pivotal Phase 3 study evaluating the safety and efficacy of the once weekly somatrogon (hGH-CTP) for treatment of growth hormone...
Aug 07, 2019 04:05 pm ET
OPKO Health Reports 2019 Second Quarter Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended June 30, 2019. Business Highlights RAYALDEE total prescriptions reported by IQVIA increased 92% in 2Q 2019 compared with 2Q 2018:  Total...
Aug 01, 2019 08:00 am ET
BIOREFERENCE LABORATORIES SELECTED AS PREFERRED LABORATORY PROVIDER BY THE IPA ASSOCIATION OF AMERICA
BioReference Laboratories, Inc., one of the largest clinical laboratories in the United States, today announced it has been selected by The IPA Association of America (TIPAAA) as its preferred provider of laboratory services and to assist with data...
Aug 01, 2019 08:00 am ET
OPKO Health to Report Second Quarter 2019 Financial Results on August 7, 2019
OPKO Health, Inc. (NASDAQ: OPK) plans to report its operating and financial results for the three months ended June 30, 2019, as well as provide guidance on expected revenues and operating expenses for the third quarter 2019, after the close of the...
Jul 01, 2019 09:29 am ET
OPKO Health’s BioReference Laboratories Forms a Strategic Collaboration With SOMOS to Improve Health Outcomes of Underserved New Yorkers
OPKO Health (NASDAQ: OPK) announced that its subsidiary, BioReference Laboratories, one of the largest clinical laboratories in the United States, has been selected by SOMOS, a physician-led network of more than 2,500 health care providers serving...
Jul 01, 2019 08:00 am ET
BioReference Laboratories Forms a Strategic Collaboration with SOMOS to Improve Health Outcomes of Underserved New Yorkers
BioReference Laboratories, Inc., an OPKO Health (NASDAQ: OPK) company and one of the largest clinical laboratories in the United States, has been selected by SOMOS, a physician-led network of more than 2,500 health care providers serving over...
Jun 28, 2019 08:00 am ET
Novitas Issues Proposed Local Coverage Determination for the 4Kscore® Test
OPKO Health, Inc. (NASDAQ: OPK) today announced that Novitas Solutions, Inc. has issued a new proposed local coverage determination (LCD) for the 4Kscore® test, with defined coverage criteria.  Under the LCD, Medicare will reimburse the test for...
Jun 20, 2019 08:00 am ET
OPKO Health Submits De Novo Request to the U.S. FDA for the 4Kscore® Test
OPKO Health, Inc. (NASDAQ: OPK) announces that the Company has submitted a de novo request to the U.S. Food and Drug Administration (FDA) seeking regulatory clearance for the 4Kscore® test. The 4Kscore® test is a blood test used by health care...
Jun 07, 2019 07:00 am ET
BioReference Laboratories Supports Man Cave Health During National Men’s Health Month
BioReference Laboratories, Inc., along with its specialty oncology and urology division, GenPath, announce today their support of Man Cave Health’s upcoming charity golf tournament for Men’s Health Month, observed annually in the United States...
May 17, 2019 08:30 am ET
Aerobic Vaginitis (AV) Testing Now Available At BioReference Laboratories
BioReference Laboratories, Inc., an OPKO Health company, along with its specialty women’s health division, GenPath, today announces the launch of new testing for aerobic vaginitis (AV). AV is a vaginal infection caused by the overgrowth of...
May 07, 2019 04:20 pm ET
OPKO Health Reports 2019 First Quarter Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2019. Business Highlights RAYALDEE total prescriptions reported by IQVIA increased 121% in 1Q 2019 compared with 1Q 2018:...
May 02, 2019 05:05 pm ET
BioReference Laboratories to Present at ACOG 2019, Demonstrating Commitment to the Research of Hereditary Conditions
BioReference Laboratories, Inc., an OPKO Health Company, along with its women’s health division GenPath, today announced the presentation of new research from its prenatal and hereditary cancer assessment programs at the 2019 American College of...
Apr 30, 2019 08:00 am ET
OPKO Health to Report First Quarter 2019 Financial Results on May 7, 2019
OPKO Health, Inc. (NASDAQ: OPK) plans to report its operating and financial results for the three months ended March 31, 2019, as well as provide guidance on expected revenues and operating expenses for the second quarter 2019, after the close of...
Apr 17, 2019 11:32 am ET
BioReference Laboratories Recognized by Forbes as Best Large Employer of 2019
BioReference Laboratories, Inc., an OPKO Health Company (NYSE:OPK), is pleased to announce it has been recognized by Forbes as one of America’s Best Large Employers of 2019. This list includes 500 large companies, and BioReference is one of only 15...
Apr 15, 2019 08:30 am ET
Recent Analysis Shows Extra Space Storage, OPKO Health, El Pollo Loco, Willis Towers Watson Public, Molina Healthcare, and Akari Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Extra Space Storage Inc (NYSE:EXR), OPKO Health, Inc. (NASDAQ:OPK), El Pollo...
Apr 12, 2019 08:00 am ET
OPKO Reports Additional Oxyntomodulin, OPK-88003, Results From Phase 2 Diabetes and Obesity Trial
OPKO Health, Inc. (NASDAQ: OPK) today reported additional results from the per protocol patient population from the Phase 2 dose escalation trial of OPK-88003 to treat type 2 diabetes and obesity. Topline data were previously reported on March...
Mar 21, 2019 08:00 am ET
OPKO Announces Positive Topline Results In Phase 2 Diabetes And Obesity Trial
OPKO Health, Inc. (NASDAQ: OPK) today announced positive topline results from a Phase 2 dose escalation trial of OPK88003 to treat type 2 diabetes and obesity.  OPK88003 is a once-weekly injectable oxyntomodulin compound with glucagon-like-peptide...
Feb 27, 2019 04:05 pm ET
OPKO Health Reports 2018 Fourth Quarter Business Highlights and Financial Results
OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended December 31, 2018. Business Highlights RAYALDEE total prescriptions reported by IQVIA increased 166% in 4Q 2018...
Feb 26, 2019 08:00 am ET
OPKO Health to Announce Fourth Quarter 2018 Financial Results on February 27, 2019
OPKO Health, Inc. (NASDAQ: OPK) plans to announce its operating and financial results for the three and twelve months ended December 31, 2018 as well as provide guidance on expected revenues and operating expenses for the first quarter 2019 after...
Feb 13, 2019 08:30 am ET
Research Report Identifies Cognizant Technology Solutions, OPKO Health, MedEquities Realty Trust, AXT, Red Robin Gourmet Burgers, and Dorian LPG with Renewed Outlook — Fundamental Analysis, Calculatin
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Cognizant Technology Solutions Corporation (NASDAQ:CTSH), OPKO Health, Inc....
Feb 05, 2019 08:30 am ET
OPKO Health, Inc. Announces the Pricing of its Offering of Convertible Senior Notes
OPKO Health, Inc. (“OPKO Health” or the “Company”) (NASDAQ: OPK) today announced the pricing of its offering of $200 million aggregate principal amount of Convertible Senior Notes due 2025 (the “Notes”). The Notes will be general senior unsecured...
Feb 04, 2019 11:30 pm ET
Johnson Fistel, LLP Announces Investigations of AbbVie Inc., Macquarie Infrastructure Corporation, OPKO Health, Inc. and Uxin Limited; Investors Encouraged to Contact Firm
SAN DIEGO, Feb. 5, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against the following companies:
Feb 04, 2019 04:20 pm ET
OPKO Health, Inc. Announces Proposed Offering of Convertible Senior Notes
OPKO Health, Inc. (“OPKO Health” or the “Company”) (NASDAQ: OPK) today announced that, subject to market and other conditions, it intends to offer $200 million aggregate principal amount of Convertible Senior Notes due 2025 (the “Notes”) in an...
Feb 01, 2019 08:00 am ET
OPKO Health Receives FDA Approval for the Point-of-Care Sangia PSA Test with the Claros® 1 Analyzer
OPKO Health, Inc. (NASDAQ: OPK) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s point-of-care Sangia Total Prostate Specific Antigen (PSA) Test using the Claros 1 Analyzer.  The product is indicated to...
Jan 31, 2019 09:15 pm ET
OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator
OPKO Health, Inc. (NASDAQ: OPK) today announced an update on the ongoing development plans of OPK-88004, a selective androgen receptor modulator (SARM). OPK-88004 has the ability to serve as an antagonist to androgen receptors in the prostate,...
Jan 31, 2019 08:00 pm ET
Future Non-Coverage Determination for 4Kscore Test Posted by Novitas
OPKO Health, Inc. (NASDAQ: OPK) today announced that Novitas Solutions, Inc. has issued a notice of a future non-coverage determination for the 4Kscore test® to be effective March 20, 2019. The notice released by Novitas today does not appear to be...
Jan 28, 2019 07:30 am ET
BioReference Laboratories Supports Federal Employees Amidst Government Shutdown
BioReference Laboratories Inc., an OPKO Health Company (NASDAQ: OPK), today announced that they will offer flexible payment arrangements for federal employees affected by the government shutdown. “We recognize the challenging financial position...
Jan 07, 2019 06:00 am ET
OPKO Health Appoints Jon R. Cohen, M.D. Executive Chairman of BioReference Laboratories
OPKO Health, Inc. (NASDAQ: OPK) today announced the appointment of Jon R. Cohen, M.D. as Executive Chairman of BioReference Laboratories. BioReference, with its GeneDx unit, is the third largest clinical laboratory in the United States. OPKO also...
Dec 27, 2018 03:34 pm ET
OPKO Health and OPKO's CEO and Chairman, Dr. Phillip Frost, Announce Proposed Resolution of SEC Action
MIAMI, Dec. 27, 2018 /PRNewswire/ -- In a settlement, subject to court approval, OPKO Health, Inc. (NASDAQ: OPK) and OPKO's CEO and Chairman, Dr. Phillip Frost, have agreed with the Securities and Exchange Commission to resolve the action brought against them in SEC v. Honig et al., 18 Civ. 08175 (S.D.N.Y).
Nov 12, 2018 05:43 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OPK, HON, DY and RYAAY
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Nov 12, 2018 12:44 pm ET
DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against OPKO Health, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against OPKO Health, Inc. (“OPKO” or “the Company”) (NASDAQ:
Nov 12, 2018 12:17 pm ET
DEADLINE TOMORROW for OPK, TRCO and USAT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Nov 11, 2018 10:00 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OPK, ABBV, MGTI, HAS and CPB
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Nov 09, 2018 07:31 pm ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in OPKO Health, Inc. of Class Action Lawsuit and Upcoming Deadline – OPK
Pomerantz LLP announces that a class action lawsuit has been filed against OPKO Health, Inc. (“OPKO” or the “Company”) (NASDAQ:  OPK) and certain of its officers.   The class action, filed in United States District Court, Southern District of...
Nov 09, 2018 04:01 pm ET
OPKO Health Reports Third Quarter 2018 Financial Results
OPKO Health, Inc. (NASDAQ:OPK) reports financial results and business highlights for the three months ended September 30, 2018. Financial Highlights Net loss for the three months ended September 30, 2018 decreased by 23% to $27.7 million or $0.05...
Nov 09, 2018 03:41 pm ET
TUESDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against OPKO Health, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against OPKO Health, Inc. (“OPKO” or “the Company”) (NASDAQ: OPK) for violations of §§10(b) and 20(a) of the Securities Exchange Act...
Nov 09, 2018 02:00 pm ET
KESSLER TOPAZ MELTZER & CHECK, LLP:  Final Deadline Reminder for OPKO Health, Inc. Investors – OPK
Kessler Topaz Meltzer & Check, LLP reminds OPKO Health, Inc. (Nasdaq:  OPK) (“OPKO”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of purchasers of...
Nov 08, 2018 05:50 pm ET
SHAREHOLDER ALERT: OPK TRCO USAT APOG MGTI HAS HTHT OZK DY FIT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Nov 08, 2018 01:00 pm ET
CLASS ACTION UPDATE for OPK, ALNY and CHGG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Nov 08, 2018 12:30 pm ET
BioReference Laboratories Named as Preferred Laboratory with Horizon Healthcare Services
BioReference Laboratories, Inc. (BRL), an OPKO Health (NASDAQ: OPK) company and the third largest clinical laboratory in the United States, will remain an in-network provider with Horizon Health Services, Inc. (Horizon), New Jersey’s oldest and...
Nov 08, 2018 09:12 am ET
OPKO Health to Announce Third Quarter 2018 Financial Results on November 9, 2018
OPKO Health, Inc. (NASDAQ: OPK) plans to announce its operating and financial results for the three and nine months ended September 30, 2018 after the close of the U.S. financial markets on Friday, November 9, 2018. OPKO’s senior management will...
Nov 08, 2018 07:55 am ET
Consolidated Research: 2018 Summary Expectations for AGCO, MDU Resources Group, Opko Health, Clean Harbors, LCI Industries, and Marathon Petroleum — Fundamental Analysis, Key Performance Indications
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AGCO Corporation (NYSE:AGCO), MDU Resources Group, Inc. (NYSE:MDU), Opko...
Nov 07, 2018 04:44 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in OPKO Health, Inc. of Class Action Lawsuit and Upcoming Deadline - OPK
NEW YORK, Nov. 7, 2018 /CNW/ -- Pomerantz LLP announces that a class action lawsuit has been filed against OPKO Health, Inc. ("OPKO" or the "Company") (NASDAQ:  OPK) and certain of its officers.   The class action, filed in United States District Court, Southern District of Florida, and indexed under 18-cv-23924, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired OPKO securities between September 26, 2013 and September 7, 2018, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the
Nov 07, 2018 04:44 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in OPKO Health, Inc. of Class Action Lawsuit and Upcoming Deadline - OPK
NEW YORK, Nov. 7, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against OPKO Health, Inc. ("OPKO" or the "Company") (NASDAQ:  OPK) and certain of its officers.   The class action, filed in United States District Court, Southern District of Florida, and indexed under 18-cv-23924, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise acquired OPKO securities between September 26, 2013 and September 7, 2018, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations
Nov 07, 2018 04:10 pm ET
6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against OPKO Health, Inc. and Encourages Investors with Losses in Excess of $750,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 7, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against OPKO Health, Inc. ("OPKO" or "the Company") (NASDAQ: OPK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Nov 07, 2018 02:28 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OPK, MCHP, ALNY and CHGG
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Nov 06, 2018 04:48 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In OPKO Health, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in OPKO Health, Inc. (“OPKO” or the “Company”) (NASDAQ:OPK) of the November 13, 2018 deadline to seek the role of lead plaintiff in a federal securities class action...
Nov 06, 2018 03:59 pm ET
SHAREHOLDER ALERT: OPK APOG ALNY MGTI CPB CHGG DY IGC FIT SYF: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Nov 06, 2018 03:43 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against OPKO Health, MGT Capital, and Applied Optoelectronics and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of OPKO Health, Inc., MGT Capital Investments, Inc., and Applied Optoelectronics, Inc.  Stockholders have until the deadlines...
Nov 06, 2018 10:26 am ET
INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against OPKO Health, Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP reminds OPKO Health, Inc. (Nasdaq: OPK) (“OPKO”) investors that a securities fraud class action lawsuit has been filed on behalf of purchasers of OPKO securities between September 26, 2013 and September 7, 2018, inclusive (the “Class Period”).
Nov 06, 2018 08:10 am ET
November 13th Deadline in Lawsuit for investors in shares of OPKO Health, Inc. (NASDAQ: OPK) announced by Shareholders Foundation
The Shareholders Foundation, Inc. announces that a deadline is comping up on November 13th, 2018 in the lawsuit that was filed for certain investors in shares of OPKO Health, Inc. (NASDAQ: OPK). The plaintiff seeks to recover losses for...
Nov 05, 2018 05:13 pm ET
CLASS ACTION UPDATE for OPK, ABBV and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Nov 05, 2018 12:51 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OPK, MCHP, ABBV, ALNY and CHGG
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Nov 05, 2018 10:33 am ET
November 13th OPKO Deadline: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against OPKO Health, Inc. - OPK
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the important November 13, 2018 lead plaintiff deadline in the shareholder class action lawsuit against OPKO Health, Inc. (“OPKO” or the “Company”)...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.